Hepatocellular Carcinoma Clinical Trials in Houston, Texas

15 studies are recruiting for hepatocellular carcinoma in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

   This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in pa…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Houston, Texas

   Locations

   219 in total

   Run by

   AstraZeneca

   See if you can join NCT06921785 on ClinicalTrials.gov

2. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center /ID# 255131, Houston, Texas

   Locations

   54 in total

   Run by

   AbbVie

   See if you can join NCT06084481 on ClinicalTrials.gov

3. First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

   This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Houston, Texas

   Locations

   21 in total

   Run by

   AstraZeneca

   See if you can join NCT06795022 on ClinicalTrials.gov

4. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

5. IDOV-Immune for Advanced Solid Tumors

   This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   5 in total

   Run by

   ViroMissile, Inc.

   See if you can join NCT06910657 on ClinicalTrials.gov

6. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

   This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston, Texas

   Locations

   62 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT05208762 on ClinicalTrials.gov

7. A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

   To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imaging.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07116486 on ClinicalTrials.gov

8. A Study of ZW251 in Participants With Advanced Solid Tumors

   The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   25 in total

   Run by

   Zymeworks BC Inc.

   See if you can join NCT07164313 on ClinicalTrials.gov

9. A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

   The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   21 in total

   Run by

   Tvardi Therapeutics, Incorporated

   See if you can join NCT05440708 on ClinicalTrials.gov

10. Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines

    This study evaluates a concept called 'Teaching the Teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "Teaching the Teachers" involves teaching the guidelines to experts who later teach the same guidelines to other radiologists, trainees, and …

    Stage

    Not phased

    Ages

    Any age

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05143619 on ClinicalTrials.gov

11. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

    This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    5 in total

    Run by

    7 Hills Pharma, LLC

    See if you can join NCT06362369 on ClinicalTrials.gov

12. Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

    The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combinat…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Houston Methodist Hospital Cancer Center, Houston, Texas

    Locations

    12 in total

    Run by

    Replimune, Inc.

    See if you can join NCT05733598 on ClinicalTrials.gov

13. Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

    This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Houston Methodist Neal Cancer Center, Houston, Texas

    Locations

    3 in total

    Run by

    Anwaar Saeed

    See if you can join NCT06698250 on ClinicalTrials.gov

14. Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

    The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly c…

    Stage

    Phase 1

    Ages

    Up to 21

    Site

    Houston Methodist Hospital, Houston, Texas

    Run by

    Baylor College of Medicine

    See if you can join NCT06198296 on ClinicalTrials.gov

15. Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

    Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and be…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Houston Methodist Research Institute, Houston, Texas

    Run by

    The Methodist Hospital Research Institute

    See if you can join NCT05185505 on ClinicalTrials.gov